180 related articles for article (PubMed ID: 38319156)
41. The ins and outs of type I iNKT cell development.
Shissler SC; Webb TJ
Mol Immunol; 2019 Jan; 105():116-130. PubMed ID: 30502719
[TBL] [Abstract][Full Text] [Related]
42. Critical role for invariant chain in CD1d-mediated selection and maturation of Vα14-invariant NKT cells.
Sillé FC; Martin C; Jayaraman P; Rothchild A; Besra GS; Behar SM; Boes M
Immunol Lett; 2011 Sep; 139(1-2):33-41. PubMed ID: 21565221
[TBL] [Abstract][Full Text] [Related]
43. The Role of Adaptor Proteins in the Biology of Natural Killer T (NKT) Cells.
Gerth E; Mattner J
Front Immunol; 2019; 10():1449. PubMed ID: 31293596
[TBL] [Abstract][Full Text] [Related]
44. Lysophospholipid presentation by CD1d and recognition by a human Natural Killer T-cell receptor.
López-Sagaseta J; Sibener LV; Kung JE; Gumperz J; Adams EJ
EMBO J; 2012 Apr; 31(8):2047-59. PubMed ID: 22395072
[TBL] [Abstract][Full Text] [Related]
45. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.
Nowak M; Arredouani MS; Tun-Kyi A; Schmidt-Wolf I; Sanda MG; Balk SP; Exley MA
PLoS One; 2010 Jun; 5(6):e11311. PubMed ID: 20593019
[TBL] [Abstract][Full Text] [Related]
46. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11.
Montoya CJ; Pollard D; Martinson J; Kumari K; Wasserfall C; Mulder CB; Rugeles MT; Atkinson MA; Landay AL; Wilson SB
Immunology; 2007 Sep; 122(1):1-14. PubMed ID: 17662044
[TBL] [Abstract][Full Text] [Related]
47. Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptors.
Patterson S; Chaidos A; Neville DC; Poggi A; Butters TD; Roberts IA; Karadimitris A
J Immunol; 2008 Sep; 181(5):3268-76. PubMed ID: 18713998
[TBL] [Abstract][Full Text] [Related]
48. Methods for Studying Mouse and Human Invariant Natural Killer T Cells.
Zhou Y; Li YR; Zeng S; Yang L
Methods Mol Biol; 2021; 2388():35-57. PubMed ID: 34524660
[TBL] [Abstract][Full Text] [Related]
49. Utilization of invariant natural killer T cells for gastric cancer treatment.
Xu Q; Li J; Zhang N; Zhang L; Qian R
Future Oncol; 2018 Aug; 14(20):2053-2066. PubMed ID: 30051730
[TBL] [Abstract][Full Text] [Related]
50. Decreased invariant natural killer T-cell-mediated antitumor immune response in patients with gastric cancer.
Ascui G; Gálvez-Jirón F; Kramm K; Schäfer C; Siña J; Pola V; Cristi F; Hernández C; Garrido-Tapia M; Pesce B; Bustamante M; Fluxá P; Molina MC; Ribeiro CH
Immunol Cell Biol; 2020 Jul; 98(6):500-513. PubMed ID: 32189398
[TBL] [Abstract][Full Text] [Related]
51. Unique interplay between sugar and lipid in determining the antigenic potency of bacterial antigens for NKT cells.
Girardi E; Yu ED; Li Y; Tarumoto N; Pei B; Wang J; Illarionov P; Kinjo Y; Kronenberg M; Zajonc DM
PLoS Biol; 2011 Nov; 9(11):e1001189. PubMed ID: 22069376
[TBL] [Abstract][Full Text] [Related]
52. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.
Croudace JE; Curbishley SM; Mura M; Willcox CR; Illarionov PA; Besra GS; Adams DH; Lammas DA
BMC Immunol; 2008 Dec; 9():71. PubMed ID: 19055753
[TBL] [Abstract][Full Text] [Related]
53. Dissociated expression of natural killer 1.1 and T-cell receptor by invariant natural killer T cells after interleukin-12 receptor and T-cell receptor signalling.
Emoto M; Shimizu T; Koike H; Yoshizawa I; Hurwitz R; Kaufmann SH; Emoto Y
Immunology; 2010 Jan; 129(1):62-74. PubMed ID: 20028429
[TBL] [Abstract][Full Text] [Related]
54. Anti-CD1d treatment suppresses immunogenic maturation of lung dendritic cells dependent on lung invariant natural killer T cells in asthmatic mice.
Lin Q; Wang T; Zuo X; Ni H; Zhong J; Zhan L; Cheng H; Huang Y; Ding X; Yu H; Nie H
Int Immunopharmacol; 2023 Nov; 124(Pt B):110921. PubMed ID: 37725846
[TBL] [Abstract][Full Text] [Related]
55. Human and mouse type I natural killer T cell antigen receptors exhibit different fine specificities for CD1d-antigen complex.
Wun KS; Ross F; Patel O; Besra GS; Porcelli SA; Richardson SK; Keshipeddy S; Howell AR; Godfrey DI; Rossjohn J
J Biol Chem; 2012 Nov; 287(46):39139-48. PubMed ID: 22995911
[TBL] [Abstract][Full Text] [Related]
56. Immunomodulatory Functions of α-GalCer and a Derivative, α-Carba-GalCer.
Satoh M; Iwabuchi K
Methods Mol Biol; 2023; 2613():1-11. PubMed ID: 36587066
[TBL] [Abstract][Full Text] [Related]
57. Fas/FasL interaction mediates imbalanced cytokine/cytotoxicity responses of iNKT cells against Jurkat cells.
Dou R; Hong Z; Tan X; Hu F; Ding Y; Wang W; Liang Z; Zhong R; Wu X; Weng X
Mol Immunol; 2018 Jul; 99():145-153. PubMed ID: 29783159
[TBL] [Abstract][Full Text] [Related]
58. Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression.
Ni C; Wu P; Wu X; Zhang T; Zhang T; Wang Z; Zhang S; Qiu F; Huang J
Cancer Lett; 2015 Jan; 356(2 Pt B):579-88. PubMed ID: 25304368
[TBL] [Abstract][Full Text] [Related]
59. CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells.
Haraguchi K; Takahashi T; Nakahara F; Matsumoto A; Kurokawa M; Ogawa S; Oda H; Hirai H; Chiba S
Leuk Lymphoma; 2006 Oct; 47(10):2218-23. PubMed ID: 17071498
[TBL] [Abstract][Full Text] [Related]
60. T Cell Receptor Expression Timing and Signal Strength in the Functional Differentiation of Invariant Natural Killer T Cells.
Dashtsoodol N; Bortoluzzi S; Schmidt-Supprian M
Front Immunol; 2019; 10():841. PubMed ID: 31080448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
